NASDAQ:ZURA Zura Bio Q2 2026 Earnings Results & Report $1.08 -0.16 (-12.90%) Closing price 04:00 PM EasternExtended Trading$1.08 +0.00 (+0.09%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zura Bio reported Q2 2026 earnings on June 30, 2026. The company reported EPS of -$0.21. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateJune 30, 2026TimeBefore Market Opens Zura Bio EPS ResultsActual EPS-$0.21Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersZura Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Zura Bio Q2 2026 Earnings FAQ Did Zura Bio beat earnings estimates for Q2 2026? Zura Bio (NASDAQ:ZURA) reported earnings of -$0.21 per share for Q2 2026. The report was announced on Tuesday, June 30, 2026. Zura Bio Earnings HeadlinesZura Bio Limited (ZURA) Securities Investigation Notice - Levi & KorsinskyNovember 16 at 10:01 AM | prnewswire.comLevi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Zura Bio Limited (ZURA)November 12, 2026 | globenewswire.comYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.November 16 at 1:00 AM | Profits Run (Ad)Zura Bio (ZURA) Set to Release Earnings on ThursdayNovember 11, 2026 | americanbankingnews.comBiotech Stocks In Focus: PEPG Jumps 114%, ZURA Rises 15%, NTHI Gains 13%November 10, 2026 | rttnews.comZURA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zura Bio LimitedNovember 10, 2026 | prnewswire.comSee More Zura Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email. Email Address About Zura BioZura Bio (NASDAQ:ZURA) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. Its research targets immune pathways that may contribute to a range of chronic conditions. The company’s investigational pipeline includes tibulizumab (ZB-106), a dual-targeting antibody designed to inhibit BAFF and IL-17A, and ZB-168, an antibody targeting the IL-7 receptor alpha. These candidates are being developed for potential use in autoimmune and inflammatory conditions. Zura Bio became a publicly traded company in 2023 through a business combination with JATT Acquisition Corp. Its drug candidates remain investigational and have not been approved for commercial use.View Zura Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.